Abbott Laboratories $ABT Shares Sold by Nelson Capital Management LLC

Nelson Capital Management LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 5.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,380 shares of the healthcare product maker’s stock after selling 270 shares during the quarter. Nelson Capital Management LLC’s holdings in Abbott Laboratories were worth $596,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Northern Financial Advisors Inc increased its position in Abbott Laboratories by 10.8% during the 2nd quarter. Northern Financial Advisors Inc now owns 1,914 shares of the healthcare product maker’s stock worth $260,000 after purchasing an additional 186 shares during the period. WoodTrust Financial Corp increased its position in Abbott Laboratories by 136.7% during the 2nd quarter. WoodTrust Financial Corp now owns 14,137 shares of the healthcare product maker’s stock worth $1,923,000 after purchasing an additional 8,165 shares during the period. Winthrop Advisory Group LLC grew its holdings in Abbott Laboratories by 2.9% during the second quarter. Winthrop Advisory Group LLC now owns 2,997 shares of the healthcare product maker’s stock worth $408,000 after acquiring an additional 84 shares during the period. Hendley & Co. Inc. grew its holdings in Abbott Laboratories by 2.6% during the second quarter. Hendley & Co. Inc. now owns 107,120 shares of the healthcare product maker’s stock worth $14,569,000 after acquiring an additional 2,710 shares during the period. Finally, Abel Hall LLC grew its holdings in Abbott Laboratories by 4.8% during the second quarter. Abel Hall LLC now owns 2,237 shares of the healthcare product maker’s stock worth $304,000 after acquiring an additional 103 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, July 17th. Leerink Partnrs upgraded shares of Abbott Laboratories to a “hold” rating in a research report on Monday, June 16th. Royal Bank Of Canada upped their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. Mizuho upped their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a report on Wednesday, July 16th. Finally, Morgan Stanley upped their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $146.24.

Abbott Laboratories Stock Down 0.5%

ABT stock opened at $133.05 on Wednesday. The company’s 50 day simple moving average is $132.19 and its 200-day simple moving average is $131.45. The firm has a market capitalization of $231.58 billion, a PE ratio of 16.67, a P/E/G ratio of 2.54 and a beta of 0.69. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.